CombiPatch and Climara Pro: History and Development of the Combination Estradiol Patch

Why a Combination Patch Was Needed in the First Place

Estrogen therapy reliably relieves vasomotor symptoms, protects bone density, and addresses genitourinary changes after menopause. The problem, identified in the late 1970s, was unopposed estrogen. Women with an intact uterus who took estrogen alone faced a sharply elevated risk of endometrial hyperplasia and cancer. Data from the 1970s and 1980s showed that unopposed oral estrogen raised endometrial cancer risk by a factor of two to twelve, depending on dose and duration.

Adding a progestogen fixed that risk, but it added a pill. Oral progestogens brought their own side-effect burden: bloating, mood changes, and for some women, a return of premenstrual-like symptoms. The pharmaceutical logic for a combined patch was straightforward: if both hormones can cross skin effectively, you could eliminate the oral progestogen entirely while still protecting the endometrium.

The Skin as a Delivery Route: Why Transdermal Changes the Pharmacology

Oral estradiol undergoes extensive first-pass metabolism in the gut and liver, converting largely to estrone and generating estrogen metabolites that alter clotting factor synthesis. Transdermal delivery bypasses this entirely. Transdermal estradiol maintains a more physiological estradiol-to-estrone ratio and produces lower circulating levels of sex hormone-binding globulin (SHBG) than equivalent oral doses.

For women, that SHBG difference matters. Higher SHBG binds testosterone and can blunt libido. The transdermal route keeps SHBG closer to baseline, which is one reason some clinicians prefer it for women reporting androgen-related complaints alongside menopausal symptoms.

The first-pass bypass also means transdermal estradiol appears to carry a lower venous thromboembolism (VTE) risk than oral formulations. A large pharmacoepidemiology study published in the BMJ found no significantly elevated VTE risk with transdermal estradiol, whereas oral estradiol was associated with an approximately two-fold increase.

The Endometrial Protection Problem Drives Innovation

Once the clinical rationale for transdermal progestogen delivery was established, the engineering question became: can you load two molecules with very different physicochemical properties into a single matrix and get reliable skin penetration for both? Norethindrone acetate and levonorgestrel are both lipophilic enough to cross the stratum corneum, which made them better candidates than more hydrophilic progestogens such as medroxyprogesterone acetate (MPA). That selectivity shaped which progestogens ended up in approved patches.

The Development Timeline: From Single-Hormone Patches to Combination Systems

1970s to 1980s: Laying the Groundwork

Transdermal estradiol patches were first studied in the late 1970s. Alza Corporation, later acquired by Johnson and Johnson, pioneered reservoir-based membrane-controlled delivery systems. The first transdermal estradiol patch (Estraderm) received FDA approval in 1986, demonstrating that clinically meaningful serum estradiol levels could be achieved through intact skin.

Endometrial protection with oral progestogens was by then standard of care for women with a uterus, but the two-component regimen, a patch plus a pill, was inconvenient. Patient adherence studies from the early 1990s consistently showed that women were more likely to miss the oral progestogen than the patch.

1990s: Matrix Technology and the Move Toward Combination

Noven Pharmaceuticals developed a drug-in-adhesive matrix technology that replaced the earlier fluid-reservoir design. A matrix patch embeds both drug molecules directly into the adhesive layer, eliminating the risk of leakage and allowing thinner, more flexible patches. This was the engineering platform that made a dual-hormone patch feasible.

Noven licensed the CombiPatch technology and entered into clinical development in the mid-1990s. The key program studied two progestogen doses, 0.14 mg/day and 0.25 mg/day of norethindrone acetate (NETA), combined with 0.05 mg/day of estradiol, applied twice weekly. Phase III trials confirmed that both NETA doses achieved endometrial protection with amenorrhea rates comparable to combined oral regimens, while the estrogen component adequately controlled vasomotor symptoms.

CombiPatch received FDA approval in 1998, marking the first combination estradiol/progestogen transdermal patch approved in the United States.

Early 2000s: Climara Pro and Once-Weekly Delivery

Berlex Laboratories (later Bayer) pursued a once-weekly combination patch using levonorgestrel rather than NETA as the progestogen. Levonorgestrel has a long history in contraception and is highly lipophilic, making it well suited to transdermal delivery. The patch, branded Climara Pro, combined 0.045 mg/day estradiol with 0.015 mg/day levonorgestrel in a single matrix worn for seven days.

The key clinical trial for Climara Pro demonstrated statistically significant reductions in moderate-to-severe hot flushes compared with placebo, with endometrial biopsy data at 12 months showing no hyperplasia in women using the active patch. That 2003 to 2004 continuous combined transdermal HRT trial was the key registration study, and it remains one of the most cited pieces of evidence for the once-weekly combination patch approach.

Climara Pro received FDA approval in 2003, five years after CombiPatch and offering the convenience of once-weekly rather than twice-weekly application.

How Each Patch Works: Mechanism of Action

Estradiol: The Active Estrogen

Both patches deliver 17-beta-estradiol, the bioidentical form of the primary estrogen produced by the premenopausal ovary. Once it crosses the stratum corneum and enters systemic circulation, estradiol binds estrogen receptors (ERalpha and ERbeta) in the hypothalamus, vaginal epithelium, bone, cardiovascular tissue, and brain.

In the hypothalamus, estradiol modulates thermoregulatory set-point signaling, which is why it reliably reduces hot flushes and night sweats. In bone, estradiol suppresses osteoclast activity, slowing the accelerated bone resorption that accounts for the 10 to 15 percent trabecular bone loss women typically experience in the first five years after menopause. FDA-approved labeling and supporting clinical data confirm that estradiol-containing patches increase lumbar spine and hip bone mineral density compared with placebo.

In the vaginal epithelium, systemic estradiol helps maintain epithelial thickness and moisture, though local vaginal estrogen often provides more targeted genitourinary relief for women with isolated genitourinary syndrome of menopause (GSM).

The Progestogen Component: Protecting the Endometrium

Without progestogen opposition, estrogen drives endometrial proliferation. The progestogen in each patch binds progesterone receptors in the endometrium, converting it from a proliferative to a secretory state and ultimately inducing a stable, atrophic endometrium with continuous use.

NETA in CombiPatch is the acetate ester of norethindrone, which increases lipophilicity and enhances transdermal absorption. Once absorbed, it converts to norethindrone, a 19-nortestosterone derivative with moderate androgenic activity. That androgenic activity is clinically relevant: NETA may have a slightly more favorable effect on bone density than purely anti-androgenic progestogens, but it can also affect lipid profiles (modest HDL reduction) and may not be ideal for women with androgenic conditions such as PCOS who are also postmenopausal.

Levonorgestrel in Climara Pro is also a 19-nortestosterone derivative, similarly androgenic. Its pharmacokinetic profile supports once-weekly delivery with steady-state serum levels maintained across the full seven-day wear period.

Continuous Combined Versus Sequential Regimens

Both CombiPatch and Climara Pro use a continuous combined approach: progestogen is delivered every day the patch is worn, not just for part of the cycle. This means most women experience amenorrhea rather than scheduled withdrawal bleeding. That is generally preferred by postmenopausal women, but the trade-off is unpredictable breakthrough bleeding in the first three to six months of use, particularly in women who are recently postmenopausal and still have a responsive endometrium.

A practical clinical framework for the timing of patch initiation by menopausal stage:

| Life Stage | Recommended Approach | Expected Bleeding Pattern | |---|---|---| | Early postmenopause (<2 years since last period) | Consider sequential HRT first; switch to continuous combined after 1 to 2 years | Breakthrough bleeding common in first 3 to 6 months | | Late postmenopause (>2 years since last period) | Continuous combined patch appropriate as first-line | Amenorrhea expected within 3 to 6 months | | Surgical menopause (hysterectomy) | Estrogen-only patch; no progestogen needed | Not applicable | | Perimenopause | Combination patch is generally not indicated; requires specialist guidance | Variable; may worsen irregular bleeding |

Sex-Specific Pharmacology: What Women Need to Know

Pharmacokinetics Differ from Men and from Oral Dosing

Clinical pharmacokinetic studies of CombiPatch show that steady-state estradiol levels with the 0.05 mg/day patch average approximately 40 to 50 pg/mL, which falls within the physiological early follicular phase range for premenopausal women. Compared with oral conjugated equine estrogens at standard doses, transdermal estradiol produces lower peak serum levels and more stable troughs across a 24-hour period.

Body composition affects absorption. Women with higher subcutaneous fat at the application site may show slightly higher absorption variability. Rotating sites, typically the lower abdomen or buttock, helps minimize this. Avoid the breast.

The Androgenic Progestogen Question in Women With PCOS

If you have PCOS and are now postmenopausal, you should discuss the androgenic progestogen profile with your prescriber. Both NETA and levonorgestrel carry androgenic activity that can, in theory, worsen lipid profiles or contribute to androgenic symptoms in susceptible women. Micronized progesterone (Prometrium) or dydrogesterone are progesterone-receptor-specific alternatives that can be paired with a single-hormone estradiol patch instead.

Bone Density Across Life Stages

The accelerated bone loss of early postmenopause is the clinical window where estrogen therapy has the clearest skeletal benefit. The Women's Health Initiative (WHI) showed that combined estrogen plus progestogen reduced hip fracture risk by 33 percent and vertebral fracture risk by 34 percent compared with placebo, though the WHI used oral conjugated estrogens plus MPA, not transdermal combinations. Transdermal-specific bone data from smaller trials are consistent in direction but lack the WHI's statistical power.

Pregnancy, Lactation, and Contraception: Required Reading

Pregnancy: Contraindicated

CombiPatch and Climara Pro are contraindicated in pregnancy. The FDA label for CombiPatch explicitly states that estrogen and progestogen combinations should not be used during pregnancy. If you are using one of these patches and discover you are pregnant, stop the patch immediately and contact your clinician.

Animal studies with norethindrone and levonorgestrel have shown virilization of female fetuses at high doses. Human epidemiological data on inadvertent first-trimester progestogen exposure have not demonstrated a consistent teratogenic signal, but the risk justifies avoidance and immediate discontinuation.

These patches are indicated for postmenopausal women, so pregnancy is rarely a practical concern. The clinical scenario where it occasionally arises is in perimenopausal women where a prescriber has used a combination patch off-label for symptom management before menopause is confirmed by 12 consecutive months of amenorrhea.

Lactation: Not Applicable, but Worth Addressing

Because these patches are indicated for postmenopausal women, lactation is almost never a concurrent clinical situation. For completeness: estradiol and synthetic progestogens both transfer into breast milk. Estrogen can suppress prolactin and reduce milk supply, so combination estrogen/progestogen preparations are generally avoided in breastfeeding women. If a perimenopausal woman who is breastfeeding (an uncommon but documented scenario) is being considered for hormonal therapy, micronized progesterone paired with low-dose topical estrogen is a more studied approach than a combination patch.

Contraception Note for Perimenopausal Women

Ovulation can occur sporadically during perimenopause. These combination patches are not contraceptive. A perimenopausal woman using a combination patch for symptom control still needs contraception if she has not completed 12 months of amenorrhea. Barrier methods or a levonorgestrel intrauterine system (which also protects the endometrium) are commonly used concurrently.

Who This Is Right for, and Who It Is Not

Women Who May Benefit Most

• Postmenopausal women with an intact uterus who want to avoid a daily oral progestogen
• Women who have difficulty tolerating oral progestogens (bloating, mood changes, headache)
• Women with a history of migraine who may tolerate steady transdermal hormone levels better than cyclical oral HRT
• Women concerned about VTE risk, given the evidence supporting a lower thrombotic profile with transdermal versus oral estrogen
• Women who prefer the convenience of once-weekly (Climara Pro) or twice-weekly (CombiPatch) application over daily pills

Women Who Should Consider Alternatives

• Women who have had a hysterectomy: estrogen-only transdermal therapy is appropriate and avoids unnecessary progestogen exposure
• Women with breast cancer or a high-risk BRCA profile: hormone therapy decisions require careful individual risk-benefit discussion; combination patches are generally avoided
• Women with a personal history of VTE or stroke: even the lower-risk transdermal route carries some concern with the progestogen component
• Women with severe androgenic PCOS in postmenopause who prefer a non-androgenic progestogen: micronized progesterone with a single-hormone patch is an alternative
• Women who are or may be pregnant

Regulatory History and Postmarket Experience

FDA Approval Trajectory

CombiPatch entered the FDA review process as a New Drug Application in the late 1990s, with Noven as the original NDA holder. It received approval in February 1998 under NDA 020375. Climara Pro followed in December 2003 under NDA 021238, with Berlex (now Bayer) as the applicant.

Both products carry the class-wide boxed warning required for all systemic estrogen-containing products since the WHI results in 2002, noting increased risks of cardiovascular events, stroke, pulmonary embolism, and breast cancer with combined estrogen/progestogen therapy.

Post-WHI Context: How the Clinical Picture Shifted

The 2002 WHI publication changed prescribing practice dramatically. Combined HRT use fell by approximately 50 percent in the years following the announcement. A 2006 analysis in JAMA found that combined HRT prescriptions in the United States declined by 66 percent between 2002 and 2003 alone.

The nuanced re-analysis of WHI data over the following decade clarified that much of the risk reported, particularly for breast cancer, cardiovascular events, and stroke, was concentrated in older women who initiated therapy more than a decade after menopause. For women under 60 or within 10 years of menopause onset, the risk-benefit balance looks considerably more favorable. This timing principle, sometimes called the "timing hypothesis," has been endorsed by The Menopause Society (formerly NAMS) in its 2022 position statement on hormone therapy.

That recalibration revived clinical interest in well-designed transdermal combination products. CombiPatch and Climara Pro have benefited from this reassessment, with prescribing recovering modestly through the 2010s and 2020s.

Generic Availability

Generic estradiol/norethindrone acetate transdermal patches became available in the United States starting around 2014, increasing access and driving down the out-of-pocket cost for women who previously could not afford branded CombiPatch.

The Evidence Base: What the Key Trials Actually Show

Continuous Combined Transdermal HRT Trial (2003 to 2004)

This key study, published in Fertility and Sterility in 2004, evaluated the once-weekly estradiol/levonorgestrel patch (the Climara Pro formulation) in 293 postmenopausal women over 12 months. The primary efficacy endpoint was reduction in moderate-to-severe vasomotor symptoms.

Key findings:

• Active patch reduced mean weekly hot flush frequency by approximately 77 percent from baseline at week 12, compared with about 51 percent for placebo
• At 12 months, endometrial biopsy showed no cases of hyperplasia in the active treatment group
• Amenorrhea rates reached 79 percent by month 12 in the active group
• The patch was well tolerated, with application-site reactions being the most common adverse event

This trial established the registration data for Climara Pro and remains a foundational reference for the clinical use of continuous combined transdermal HRT.

CombiPatch Phase III Data

The key CombiPatch trials enrolled postmenopausal women aged 40 to 65 and compared the combination patch against placebo and against oral estrogen/progestogen regimens. Phase III data showed that the 0.05 mg estradiol/0.25 mg NETA patch reduced moderate-to-severe vasomotor symptom frequency by approximately 80 percent at 12 weeks, with endometrial protection confirmed at one year.

The trial also reported bone density outcomes: lumbar spine BMD increased by approximately 3.5 percent over 12 months compared with a slight loss in the placebo group.

Evidence Gaps in Women: An Honest Assessment

The combination patch trials enrolled predominantly White, non-Hispanic postmenopausal women in their early to mid-50s. Data in Black women, Latina women, Asian women, and women with obesity are thin. Pharmacokinetic variation by body composition and skin melanin content is plausible but understudied. Long-term safety data beyond five years of continuous use remain largely extrapolated from oral HRT literature rather than directly studied in transdermal combination cohorts.

The Menopause Society has acknowledged that women of color have been historically under-represented in menopause clinical trials and calls for more diverse enrollment in future studies. You deserve to know that the evidence base for this medication, like most HRT evidence, was built largely on a narrow demographic that may not represent your own physiology and risk profile.

Practical Application: Getting the Most From Your Patch

Application Sites and Rotation

Apply CombiPatch or Climara Pro to clean, dry, intact skin on the lower abdomen or buttock. Avoid areas with skin folds, irritation, or active rashes. Rotate sites with each application to reduce local skin reactions. Do not apply to the breast. Press the patch firmly for 10 seconds and check edges are adhered.

What to Do If the Patch Falls Off

If the patch falls off within the first 24 hours of a new wear cycle, replace it and continue on the original schedule. If it falls off after 24 hours, apply a new patch and consider that your new start day. Consistent adhesion matters because serum hormone levels drop within 24 to 48 hours of patch removal.

Monitoring

Your clinician should assess:

• Symptom response at 8 to 12 weeks
• Any unscheduled vaginal bleeding (if this persists beyond 6 months, endometrial evaluation is warranted)
• Blood pressure, as estrogen therapy can mildly raise blood pressure in susceptible women
• Annual breast examination and mammography per standard screening guidelines
• Bone density at baseline and per standard USPSTF intervals for postmenopausal women

ACOG Practice Bulletin on Menopausal Hormone Therapy recommends reassessing the continued need for therapy annually and using the lowest effective dose for the shortest duration appropriate for each individual woman.